Phylogenetic analysis and structural predictions of human adenovirus penton proteins as a basis for tissue-specific adenovirus vector design

Journal of Virology

Volumn 81, Issue 15, 2007, Pages 8270-8281

  Madisch, Ijad ^a   Hofmayer, Soeren ^a   Moritz, Christian ^a   Grintzalis, Alexander ^a,c   Hainmueller, Jens ^b   Pring Akerblom, Patricia ^a   Heim, Albert ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HARVARD UNIVERSITY   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CAPSID PROTEIN; INTEGRIN; N ETHYL N [4 (4 PIPERIDINYL)BUTYRYL]GLYCYLASPARTYL 3 CYCLOHEXYLALANINAMIDE; VIRUS FIBER PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CYTOPATHOGENIC EFFECT; DRUG DESIGN; GENETIC ANALYSIS; HUMAN ADENOVIRUS; INTERNALIZATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; SIMIAN VIRUS; VIRUS CAPSID; VIRUS RECOMBINATION; VIRUS STRAIN;

ADENOVIRIDAE; AMINO ACID SEQUENCE; CAPSID; CAPSID PROTEINS; GENETIC VECTORS; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PHYLOGENY; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT;

ADENOVIRIDAE; HUMAN ADENOVIRUS; MIRIDAE; SIMIAN ADENOVIRUS;

EID: 34547121715     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00048-07     Document Type: Article

References (56)

1. Adrian, T., B. Best, and R. Wigand. 1987. Serologically atypical adenovirus strains of subgenus D are different in their genome from the respective prototypes. Med. Microbiol. Immunol. 176:217-224.
2. Adrian, T., R. Wigand, and G. Wadell. 1987. Serological and biochemical characteristics of intermediate adenovirus strains of subgenus D. Arch. Virol. 97:347-357.
3. Albinsson, B., and A. H. Kidd. 1999. Adenovirus type 41 lacks an RGD alpha(v)-integrin binding motif on the penton base and undergoes delayed uptake in A549 cells. Virus Res. 64:125-136.
4. Arnberg, N., P. Pring-Akerblom, and G. Wadell. 2002. Adenovirus type 37 uses sialic acid as a cellular receptor on Chang C cells. J. Virol. 76:8834-8841.
5. Barrett, C. P., B. A. Hall, and M. E. Noble. 2004. Dynamite: a simple way to gain insight into protein motions. Acta Crystallogr. Sect. D 60:2280-2287.
6. Boudin, M. L., M. Moncany, J. C. D'Halluin, and P. A. Boulanger. 1979. Isolation and characterization of adenovirus type 2 vertex capsomer (penton base). Virology 92:125-138.
7. Brooks, B. R., R. E. Bruccoleri, B. D. Olafson, D. J. States, S. Swaminathan, and M. Karplus. 1983. CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J. Comp. Chem. 4:187-217.
8. Chatziandreou, I., K. C. Gilmour, A. M. McNicol, M. Costabile, J. Sinclair, D. Cubitt, J. D. Campbell, C. Kinnon, W. Qasim, and H. B. Gaspar. 2007. Capture and generation of adenovirus specific T cells for adoptive immunotherapy. Br. J. Haematol. 136:117-126.
9. Davison, A. J., E. A. Telford, M. S. Watson, K. McBride, and V. Mautner. 1993. The DNA sequence of adenovirus type 40. J. Mol. Biol. 234:1308-1316.
10. Einfeld, D. A., D. E. Brough, P. W. Roelvink, I. Kovesdi, and T. J. Wickham. 1999. Construction of a pseudoreceptor that mediates transduction by adenoviruses expressing a ligand in fiber or penton base. J. Virol. 73:9130-9136.
11. Einfeld, D. A., and P. W. Roelvink. 2002. Advances towards targetable adenovirus vectors for gene therapy. Curr. Opin. Mol. Ther. 4:444-451.
12. Engelmann, I., I. Madisch, H. Pommer, and A. Heim. 2006. An outbreak of epidemic keratoconjunctivitis caused by a new intermediate adenovirus 22/H8 identified by molecular typing. Clin. Infect. Dis. 43:e64-e66.
13. Farina, S. F., G. P. Gao, Z. Q. Xiang, J. J. Rux, R. M. Burnett, M. R. Alvira, J. Marsh, H. C. Ertl, and J. M. Wilson. 2001. Replication-defective vector based on a chimpanzee adenovirus. J. Virol. 75:11603-11613.
14. Fuschiotti, P., G. Schoehn, P. Fender, C. M. Fabry, E. A. Hewat, J. Chroboczek, R. W. Ruigrok, and J. F. Conway. 2006. Structure of the dodecahedral penton particle from human adenovirus type 3. J. Mol. Biol. 356:510-520.
15. Gahery-Segard, H., F. Farace, D. Godfrin, J. Gaston, R. Lengagne, T. Tursz, P. Boulanger, and J. G. Guillet. 1998. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. 72:2388-2397.
16. Gahery-Segard, H., V. Molinier-Frenkel, C. Le Boulaire, P. Saulnier, P. Opolon, R. Lengagne, E. Gautier, A. Le Cesne, L. Zitvogel, A. Venet, C. Schatz, M. Courtney, T. Le Chevalier, T. Tursz, J. G. Guillet, and F. Farace. 1997. Phase I trial of recombinant adenovirus gene transfer in lung cancer. Longitudinal study of the immune responses to transgene and viral products. J. Clin. Investig. 100:2218-2226.
17. Gall, J., A. Kass-Eisler, L. Leinwand, and E. Falck-Pedersen. 1996. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J. Virol. 70:2116-2123.
18. Ghosh, S. S., P. Gopinath, and A. Ramesh. 2006. Adenoviral vectors: a promising tool for gene therapy. Appl. Biochem. Biotechnol. 133:9-29.
19. Harui, A., M. D. Roth, D. Vira, M. Sanghvi, H. Mizuguchi, and S. K. Basak. 2006. Adenoviral-encoded antigens are presented efficiently by a subset of dendritic cells expressing high levels of alpha(v)beta3 integrins. J. Leukoc. Biol. 79:1271-1278.
20. Hoffmann, D., A. Heim, D. M. Nettelbeck, L. Steinstraesser, and O. Wildner. 2007. Evaluation of twenty human adenovirus types and one infectivity-enhanced adenovirus for the therapy of soft-tissue sarcoma. Hum. Gene Ther. 18:51-62.
21. Hong, S. S., N. A. Habib, L. Franqueville, S. Jensen, and P. A. Boulanger. 2003. Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors. J. Virol. 77:10366-10375.
22. Hynes, R. O. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69:11-25.
23. Jones, M. S., II, B. Harrach, R. D. Ganac, M. M. Gozum, W. P. Dela Cruz, B. Riedel, C. Pan, E. L. Delwart, and D. P. Schnurr. 2007. New adenovirus species found in a patient presenting with gastroenteritis. J. Virol. 81:5978-5984.
24. Kanerva, A., M. Wang, G. J. Bauerschmitz, J. T. Lam, R. A. Desmond, S. M. Bhoola, M. N. Barnes, R. D. Alvarez, G. P. Siegal, D. T. Curiel, and A. Hemminki. 2002. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol. Ther. 5:695-704.
25. Kim, M., K. R. Zinn, B. G. Barnett, L. A. Sumerel, V. Krasnykh, D. T. Curiel, and J. T. Douglas. 2002. The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumor cells. Eur. J. Cancer 38:1917-1926.
26. Koizumi, N., K. Kawabata, F. Sakurai, Y. Watanabe, T. Hayakawa, and H. Mizuguchi. 2006. Modified adenoviral vectors ablated for coxsackievirus-adenovirus receptor, alphav integrin, and heparan sulfate binding reduce in vivo tissue transduction and toxicity. Hum. Gene Ther. 17:264-279.
27. Korner, H., U. Fritzsche, and H. G. Burgert. 1992. Tumor necrosis factor alpha stimulates expression of adenovirus early region 3 proteins: implications for viral persistence. Proc. Natl. Acad. Sci. USA 89:11857-11861.
28. Madisch, I., G. Harste, H. Pommer, and A. Heim. 2005. Phylogenetic analysis of the main neutralization and hemagglutination determinants of all human adenovirus prototypes as a basis for molecular classification and taxonomy. J. Virol. 79:15265-15276.
29. Mathias, P., T. Wickham, M. Moore, and G. Nemerow. 1994. Multiple adenovirus serotypes use alpha v integrins for infection. J. Virol. 68:6811-6814.
30. McNees, A. L., J. A. Mahr, D. Ornelles, and L. R. Gooding. 2004. Postinternalization inhibition of adenovirus gene expression and infectious virus production in human T-cell lines. J. Virol. 78:6955-6966.
31. Meier, O., and U. F. Greber. 2004. Adenovirus endocytosis. J. Gene Med. 6(Suppl. 1):S152-S163.
32. Messerle, M., I. Crnkovic, W. Hammerschmidt, H. Ziegler, and U. H. Koszinowski. 1997. Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc. Natl. Acad. Sci. USA 94: 14759-14763.
33. Molnar-Kimber, K. L., D. H. Sterman, M. Chang, E. H. Kang, M. ElBash, M. Lanuti, A. Elshami, K. Gelfand, J. M. Wilson, L. R. Kaiser, and S. M. Albelda. 1998. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum. Gene Ther. 9:2121-2133.
34. Mount, D. W. 2001. Bioinformatics: sequence and genome analysis. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
35. Nemerow, G. R. 2000. Adenoviral vectors - new insights. Trends Microbiol. 8:391-394.
36. Noureddini, S. C., and D. T. Curiel. 2005. Genetic targeting strategies for adenovirus. Mol. Pharmacol. 2:341-347.
37. Purkayastha, A., S. E. Ditty, J. Su, J. McGraw, T. L. Hadfield, C. Tibbetts, and D. Seto. 2005. Genomic and bioinformatics analysis of HAdV-4, a human adenovirus causing acute respiratory disease: implications for gene therapy and vaccine vector development. J. Virol. 79:2559-2572.
38. Rice, P., I. Longden, and A. Bleasby. 2000. EMBOSS: the European Molecular Biology Open Software Suite. Trends Genet. 16:276-277.
39. Roy, S., Y. Zhi, G. P. Kobinger, J. Figueredo, R. Calcedo, J. R. Hiller, H. Feldmann, and J. M. Wilson. 2006. Generation of an adenoviral vaccine vector based on simian adenovirus 21. J. Gen. Virol. 87:2477-2485.
40. Ruzsics, Z., M. Wagner, A. Osterlehner, J. Cook, U. Koszinowski, and H. G. Burgert. 2006. Transposon-assisted cloning and traceless mutagenesis of adenoviruses: development of a novel vector based on species D. J. Virol. 80:8100-8113.
41. + cells by an adenovirus type 35 vector. Gene Ther. 10:1041-1048.
42. Schnurr, D., and M. E. Dondero. 1993. Two new candidate adenovirus serotypes. Intervirology 36:79-83.
43. Schrader, E., and R. Wigand. 1981. Neutralization of adenovirus infectivity and cytotoxin in various cell cultures. J. Virol. Methods 2:321-330.
44. Shenk, T. 2001. Adenoviridae: the viruses and their replication. Lippincott-Raven Publishers, New York, NY.
45. Short, J. J., A. V. Pereboev, Y. Kawakami, C. Vasu, M. J. Holterman, and D. T. Curiel. 2004. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology 322:349-359.
46. Sirena, D., B. Lilienfeld, M. Eisenhut, S. Kalin, K. Boucke, R. R. Beerli, L. Vogt, C. Ruedl, M. F. Bachmann, U. F. Greber, and S. Hemmi. 2004. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J. Virol. 78:4454-4462.
47. Sirena, D., Z. Ruzsics, W. Schaffner, U. F. Greber, and S. Hemmi. 2005. The nucleotide sequence and a first generation gene transfer vector of species B human adenovirus serotype 3. Virology 343:283-298.
48. Staatz, W. D., K. F. Fok, M. M. Zutter, S. P. Adams, B. A. Rodriguez, and S. A. Santoro. 1991. Identification of a tetrapeptide recognition sequence for the alpha 2 beta 1 integrin in collagen. J. Biol. Chem. 266:7363-7367.
49. Swenson, P. D., G. Wadell, A. Allard, and J. C. Hierholzer. 2003. Adenoviruses, p. 1404-1417. In P. R. Murray, E. J. Baron, M. A. Pfaller, J. H. Jorgensen, and R. A. Yolken (ed.), Manual of clinical microbiology, vol. 2. ASM Press, Washington, DC.
50. Thirion, C., H. Lochmuller, Z. Ruzsics, M. Boelhauve, C. Konig, C. Thedieck, S. Kutik, C. Geiger, S. Kochanek, C. Volpers, and H. G. Burgert. 2006. Adenovirus vectors based on human adenovirus type 19a have high potential for human muscle-directed gene therapy. Hum. Gene Ther. 17: 193-205.
51. Wickham, T. J., M. E. Carrion, and I. Kovesdi. 1995. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther. 2:750-756.
52. Wickham, T. J., P. Mathias, D. A. Cheresh, and G. R. Nemerow. 1993. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73:309-319.
53. Wu, Q., and S. K. Tikoo. 2004. Altered tropism of recombinant bovine adenovirus type-3 expressing chimeric fiber. Virus Res. 99:9-15.
54. Young, L. S., and V. Mautner. 2001. The promise and potential hazards of adenovirus gene therapy. Gut 48:733-736.
55. Young, L. S., P. F. Searle, D. Onion, and V. Mautner. 2006. Viral gene therapy strategies: from basic science to clinical application. J. Pathol. 208: 299-318.
56. Zubieta, C., G. Schoehn, J. Chroboczek, and S. Cusack. 2005. The structure of the human adenovirus 2 penton. Mol. Cell 17:121-135.